Skip to content

Clinical and basic research on the diagnosis and treatment of cold-dampness syndrome in rheumatoid arthritis by TCM

Clinical and basic research on the diagnosis and treatment of cold-dampness syndrome in rheumatoid arthritis by TCM

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043758
Enrollment
Unknown
Registered
2021-02-27
Start date
2021-02-28
Completion date
Unknown
Last updated
2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Sponsors

Zhuhai Integrated Traditional Chinese and Western Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for patients with wind-like pass were: 18-65 years old; According to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatology (EULAR) classification criteria for wind-like classification; The syndromes of Chinese medicine accord with the syndrome of cold-dampness blockage and the syndrome of hot-dampness blockage; Signed informed consent. 2. Inclusion criteria for ankylosing spondylitis: 18-65 years old; Compliance with the New York Standards for Ankylosing Spondylitis Revised 1984; The syndromes of Chinese medicine accord with the syndrome of cold-dampness blockage; Signed informed consent. 3. Inclusion criteria for osteoarthritis: 18-65 years old; In accordance with the 1991 American College of Rheumatology (ACR) classification of osteoarthritis standards; The TCM syndromes accord with the syndrome of cold-dampness blockage; Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. With other rheumatic diseases (such as SLE, Sjogren's syndrome, systemic sclerosis, dermatomyositis, etc.); 2. Extrarticular manifestations of severe patients (such as high fever, multiple rheumatoid nodules, interstitial pneumonia, etc.); 3. patients with cardiovascular, lung, liver, kidney, hematopoietic system and other serious diseases; 4. patients with severe infection, organ failure or malignant tumor; 5. pregnant or lactating women; 6. patients with a history of mental illness and cognitive dysfunction can not cooperate.

Design outcomes

Primary

MeasureTime frame
Rheumatoid factor;

Countries

China

Contacts

Public ContactPan Hudan
panhudan1988@163.com+86 17765211265

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026